Search Results
10
Everything
Search Filters
Organization
Moleculin Biotech, Inc.
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
March 24, 2025 07:05 ET
|
Moleculin Biotech, Inc.
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently...
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
March 19, 2025 08:05 ET
|
Moleculin Biotech, Inc.
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018
February 21, 2019 16:59 ET
|
Moleculin Biotech, Inc.
HOUSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
February 20, 2019 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Approval for Third Drug to Commence Clinical Trials
February 07, 2019 07:30 ET
|
Moleculin Biotech, Inc.
MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell...
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug
February 05, 2019 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board
January 17, 2019 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland
January 09, 2019 07:30 ET
|
Moleculin Biotech, Inc.
Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the...
Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate
January 03, 2019 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018
December 11, 2018 07:30 ET
|
Moleculin Biotech, Inc.
HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...